Expertise in
27
conditions

Dr. Amanda L. Gillespie-Twardy

Hematology
Blue Ridge Cancer Center
2013 Jefferson St SW, 
Roanoke, VA 
Accepting New Patients
Offers Telehealth
Expertise in
27
conditions
Blue Ridge Cancer Center
2013 Jefferson St SW, 
Roanoke, VA 

Overview

Amanda Gillespie-Twardy is a Hematologist practicing medicine in Roanoke, Virginia.

Dr. Gillespie-Twardy is highly rated in 27 conditions, according to our data. Her clinical expertise encompasses Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Muscle Invasive Bladder Cancer, and Bone Marrow Aspiration.

She is actively involved in clinical research, co-authoring 8 peer reviewed articles and participating in 11 clinical trials. Dr. Gillespie-Twardy is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in VA

Hospital Affiliations

Carilion Medical Center
Carilion Franklin Memorial Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MVP Health
  • EPO
  • PPO
Piedmont
  • HMO
  • POS
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Blue Ridge Cancer Center
2013 Jefferson St SW, Roanoke, VA 24014

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2026
Intervention Type: Drug
Study Drugs: Imlunestrant, Exemestane, Fulvestrant, Abemaciclib
Study Phase: Phase 3
A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Participants With Metastatic Solid Malignancies
A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Participants With Metastatic Solid Malignancies
Enrollment Status: Completed
Publish Date: July 06, 2026
Intervention Type: Drug
Study Drugs: Brentuximab vedotin, Pembrolizumab
Study Phase: Phase 2
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Enrollment Status: Active_not_recruiting
Publish Date: April 24, 2026
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Idelalisib, Bendamustine, Rituximab
Study Phase: Phase 3
DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma
DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: April 23, 2026
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Daratumumab, Bortezomib, Dexamethasone
Study Phase: Phase 3
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Enrollment Status: Terminated
Publish Date: August 28, 2025
Intervention Type: Drug
Study Drugs: Brentuximab, Doxorubicin, Vinblastine, Dacarbazine, Nivolumab, Filgrastim
Study Phase: Phase 2
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Enrollment Status: Completed
Publish Date: March 30, 2025
Intervention Type: Drug
Study Drugs: Zanubrutinib, Ibrutinib
Study Phase: Phase 3
A Phase 2, Single-Arm, Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments, at Least One in the Metastatic Setting
A Phase 2, Single-Arm, Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments, at Least One in the Metastatic Setting
Enrollment Status: Terminated
Publish Date: January 29, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Sacituzumab Govitecan-hziy
Study Phase: Phase 2
SYMPHONY-II: A Phase II Open-Label, Multicenter Trial of Oral Tazemetostat in Combination With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
SYMPHONY-II: A Phase II Open-Label, Multicenter Trial of Oral Tazemetostat in Combination With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
Enrollment Status: Terminated
Publish Date: March 25, 2024
Intervention Type: Drug, Combination product
Study Drug: Tazemetostat
Study Phase: Phase 2
Randomized Crossover Ph3 to Evaluate Efficacy/Safety of Enobosarm Monotherapy vs Active Control for Treatment of AR+/ER+/HER2- MBC With AR Staining Previously Treated w/Nonsteroidal Aromatase Inhibitor, SERD & CDK 4/6 Inhibitor
Randomized Crossover Ph3 to Evaluate Efficacy/Safety of Enobosarm Monotherapy vs Active Control for Treatment of AR+/ER+/HER2- MBC With AR Staining Previously Treated w/Nonsteroidal Aromatase Inhibitor, SERD & CDK 4/6 Inhibitor
Enrollment Status: Terminated
Publish Date: January 26, 2024
Intervention Type: Drug
Study Drugs: Enobosarm, Exemestane
Study Phase: Phase 3
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drug: GC4419
Study Phase: Phase 3
View 9 Less Clinical Trials

8 Total Publications

Avasopasem manganese treatment for severe oral mucositis from chemoradiotherapy for locally advanced head and neck cancer: phase 3 randomized controlled trial (ROMAN).
Avasopasem manganese treatment for severe oral mucositis from chemoradiotherapy for locally advanced head and neck cancer: phase 3 randomized controlled trial (ROMAN).
Journal: EClinicalMedicine
Published: December 29, 2024
Similar Doctors
Expertise in
33
conditions
Expertise in
33
conditions
Referral may be required

Blue Ridge Cancer Center

2013 Jefferson St SW, 
Roanoke, VA 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Matthew Skelton is a Hematologist practicing medicine in Roanoke, Virginia. Dr. Skelton is highly rated in 33 conditions, according to our data. His clinical expertise encompasses X-Linked Creatine Deficiency, Non-Hodgkin Lymphoma, Multiple Myeloma, Hodgkin Lymphoma, and Bone Marrow Aspiration. Dr. Skelton is currently accepting new patients.

Expertise in
54
conditions
Dr. Jerome Goldschmidt
Hematology | Oncology
Expertise in
54
conditions
Dr. Jerome Goldschmidt
Hematology | Oncology
Referral may be required

Blue Ridge Cancer Care Blacksburg

2600 Research Center Dr, Ste A, 
Blacksburg, VA 
 (25.6 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jerome Goldschmidt is a Hematologist and an Oncologist practicing medicine in Blacksburg, Virginia. Dr. Goldschmidt is highly rated in 54 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Paget Disease of the Breast, Small Cell Lung Cancer (SCLC), and Pleuropulmonary Blastoma. Dr. Goldschmidt is currently accepting new patients.

Expertise in
35
conditions
Expertise in
35
conditions
Referral may be required

Lewisgale Medical Center

1900 Electric Rd, 
Salem, VA 
 (4.9 miles away)
540-774-8660
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrew Fintel is a Hematologist practicing medicine in Salem, Virginia. Dr. Fintel is highly rated in 35 conditions, according to our data. His clinical expertise encompasses Thrombocytopenia, Myelodysplastic Syndrome (MDS), Large-Cell Immunoblastic Lymphoma, Hodgkin Lymphoma, and Bone Marrow Aspiration. Dr. Fintel is currently accepting new patients.

Frequently Asked Questions about Dr. Amanda L. Gillespie-Twardy

Is Dr. Amanda L. Gillespie-Twardy a top-rated expert for Small Lymphocytic Lymphoma (SLL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Amanda L. Gillespie-Twardy is classified as an Distinguished expert for Small Lymphocytic Lymphoma (SLL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Amanda L. Gillespie-Twardy specialize in?

While Dr. Amanda L. Gillespie-Twardy is a Hematology, they have specific expertise in Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL), and Chronic B-Cell Leukemia (CBCL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Amanda L. Gillespie-Twardy participate in research or clinical trials?

Yes. Dr. Amanda L. Gillespie-Twardy has published 8 articles and abstracts on conditions like Small Lymphocytic Lymphoma (SLL). You can view a list of Dr. Amanda L. Gillespie-Twardy's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Amanda L. Gillespie-Twardy accept my insurance?

Dr. Amanda L. Gillespie-Twardy accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gillespie-Twardy's expertise for a condition
ConditionClose
    View All 26 Advanced Conditions
    View All 51 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile